Ketamine and Neuroplasticity: Understanding the Research

Neuroplasticity describes the nervous system’s capacity to change how its cells and circuits function and connect. The term appears often in ketamine advertising, but it does not by itself establish that a medication will improve symptoms or “rewire” a particular person’s brain.

Compounded ketamine is not FDA-approved. FDA has not reviewed compounded medications for safety, effectiveness, or quality before marketing. Ketamine injection is approved for anesthesia, not psychiatric disorders. Compounded ketamine nasal spray is different from Spravato, the FDA-approved esketamine product used in certified healthcare settings.

What are researchers studying?

Ketamine affects NMDA receptors, which are involved in signaling by the neurotransmitter glutamate. Researchers are also investigating other receptors, signaling pathways, and ketamine metabolites. A receptor-level effect is one piece of a complex biological process; it does not provide a complete explanation of an individual treatment outcome.

What did an often-cited animal study find?

In a 2019 NIH-supported study, researchers examined brain-cell connections in mice exposed to chronic stress. Ketamine affected dendritic spines, small structures involved in communication between neurons. The work helped researchers investigate how behavioral changes and changes in connections were related over time.

The study involved mice, not patients using a compounded nasal spray at home. Animal behavior and brain imaging findings cannot establish clinical benefit, an appropriate human dose, or lasting recovery. The distinction should remain clear whenever a research image or scientific term appears in treatment marketing.

Why “new pathways” is an incomplete promise

Depression is not diagnosed simply by counting connections, and a person’s response cannot be inferred from a diagram of receptors. Claims that treatment repairs the brain, erases trauma, or creates a predictable window for change need evidence specific to the clinical outcome being claimed.

Studies of intravenous ketamine or approved esketamine do not establish the effectiveness of a different compounded preparation. Formulation, route, dose, diagnosis, study design, and treatment setting all matter. A clinician should explain both what a study measured and what it leaves unanswered.

Questions that connect science to your care

• Was the evidence obtained in people with my diagnosis?
• Was the same formulation and route studied?
• Were symptoms and daily functioning measured, or only biological changes?
• How long did follow-up last?
• How would we track benefit and unwanted effects in my case?

An unusual sensation during treatment is not a measure of neuroplasticity. Report your experience honestly rather than trying to produce an intense effect. Clinical follow-up should focus on your health and functioning.

Risks and the treatment setting

Ketamine can cause sedation, dissociation, impaired thinking or coordination, increased blood pressure, and slowed breathing. Other concerns include abuse or misuse, worsening psychiatric symptoms, and urinary or bladder problems. A prescription or lower dose does not eliminate these risks.

At home, a healthcare professional is not onsite to monitor you or respond immediately to an adverse reaction. Virtual follow-up does not provide the same monitoring as an onsite team. Discuss whether the setting is appropriate, your medication interactions, and an emergency plan before treatment.

Discuss your questions with a clinician

Bliss Mist Rx LLC provides telehealth services and does not compound or manufacture medications. If treatment is prescribed, an independent, appropriately licensed compounding pharmacy dispenses the medication. A consultation does not guarantee a prescription; applicable prescribing and compounding requirements must be met.

Book a Free Virtual Appointment or Follow-Up to review your questions, alternatives, and next steps. This article provides general education and does not replace individualized medical advice.

Further reading: NIH: 2019 mouse study; Research on ketamine and NMDA receptors; FDA: compounded-drug risks.